J.D. Power Recognizes Fifth Third as No. 1 for Banking Mobile App User Satisfaction Among Regional Banks
CINCINNATI--(BUSINESS WIRE)--J.D. Power today recognizes Fifth Third Bank (NASDAQ: FITB) as America's best mobile banking app experience among regional banks as part of its 2025 U.S. Banking Mobile App Satisfaction Study SM. Study respondents also rate Fifth Third No. 1 for Visual Appeal.
'We're honored by this recognition from our customers,' said Ben Hoffman, chief strategy officer and head of consumer products at Fifth Third. 'Our digital teams are dedicated to delivering seamless, high-quality experiences that align with how our customers choose to bank—whether in a branch or through our app. With millions of users engaging with our digital platforms over a billion times annually, we remain committed to listening, learning, and evolving our app to meet our customers' needs and power their financial journeys.'
Fifth Third launched its next-generation mobile app in 2022, and today, more than 2.4 million users rely on it each month for seamless, everyday banking. Built to simplify financial life, the app delivers a powerful combination of innovation, usability, and personalization through industry-leading features:
Early access to pay and secure, real-time person-to-person payments, giving customers more control over their money.
A clean, modern interface with intuitive navigation, including dark mode and app theming tailored to specific customer segments.
A streamlined onboarding experience that makes switching direct deposit effortless—so customers can quickly start receiving paychecks into their Fifth Third account.
SmartShield® 1, a first-of-its-kind in-app security experience that gamifies digital safety, empowering users to protect their finances through interactive learning and proactive engagement.
Instant card controls that allow users to quickly lock or unlock their credit cards, adding flexibility and peace of mind in moments that matter.
Real-time card tracking that keeps customers informed on the status of their debit card orders—from processing to delivery—bringing added transparency to the experience.
With a relentless focus on innovation, the Bank delivered hundreds of app enhancements in 2024, reinforcing its commitment to delivering more intelligent, responsive, and user-centric digital banking experiences.
'This recognition is a testament to the deep collaboration between product, technology and design at Fifth Third,' said Jude Schramm, chief information officer at Fifth Third. 'Our teams are focused on delivering digital experiences that truly serve our customers. We're continuously evolving through thoughtful, rapid innovation to make banking simpler, more intuitive, and—ultimately—a Fifth Third better.'
Fifth Third also earned the top spot for Retail Banking Customer Satisfaction in Florida for the second year in a row as part of the J.D. Power 2025 U.S. Retail Banking Satisfaction Study SM.
About Fifth Third
Fifth Third is a bank that's as long on innovation as it is on history. Since 1858, we've been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it's one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere's World's Most Ethical Companies ® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation's highest performing regional bank, but to be the bank people most value and trust.
Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ ® Global Select Market under the symbol "FITB." Investor information and press releases can be viewed at www.53.com. Deposit and credit products provided by Fifth Third Bank, National Association. Member FDIC.
About J.D. Power
J.D. Power is a global leader in consumer insights, advisory services, and data and analytics. A pioneer in the use of big data, artificial intelligence (AI) and algorithmic modeling capabilities to understand consumer behavior, J.D. Power has been delivering incisive industry intelligence on customer interactions with brands and products for more than 55 years. The world's leading businesses across major industries rely on J.D. Power to guide their customer-facing strategies.
J.D. Power has offices in North America, Europe, and Asia Pacific. To learn more about the company's business offerings, visit JDPower.com/business. The J.D. Power auto-shopping tool can be found at JDPower.com.
Fifth Third Bank received the highest score among regional banks ($65B to $250B in deposits) in the J.D. Power 2025 U.S. Banking Mobile App Satisfaction Study, which measures customer satisfaction with financial institutions' mobile applications for banking account management. Visit jdpower.com/awards for more details.
Fifth Third Bank received the highest score in Florida in the J.D. Power 2024-2025 U.S. Retail Banking Satisfaction Studies (tied in 2025), which measure customers' satisfaction with their primary bank. Visit jdpower.com/awards for more details.
Download and use of Fifth Third mobile app is subject to Digital Services User Agreement terms and conditions.
1 Fifth Third employs a number of fraud protection measures to help protect your account. Your SmartShield dashboard is a free tool to customize alerts and help further secure your information. You may also enroll in Fifth Third Identity Alert, an optional, non-FDIC insured product with enhanced features, subject to additional fees, provided by Fifth Third's vendor, Trilegiant.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
38 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers. On July 25, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on 1) 'the iCTC completed annual scheduled maintenance in December' and 'capacity was reduced by more than half for about 1 month,' 2) "[l]ower Proleukin sales' than the company expected, and 3) 'the variable pace at which ATCs began treatment patients.' Investors and analysts reacted immediately to Iovance's revelation. The price of Iovance's common stock declined dramatically. From a closing market price of $3.17 per share on May 8, 2025, Iovance's stock price fell to $1.75 per share on May 9, 2025, a decline of about 44.795% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Iovance's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Iovance class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Yahoo
2 hours ago
- Yahoo
Microsoft Tops $3.5 Trillion Market Cap, Beats Nvidia
Microsoft (NASDAQ:MSFT) hit a new high as its market capitalization topped $3.5 trillion, edging out Nvidia (NASDAQ:NVDA) and solidifying its lead among the Magnificent Seven. Warning! GuruFocus has detected 5 Warning Sign with MSFT. Shares of Microsoft climbed to a record $467.68 on Thursday, up 0.8%, before adding another 0.6% on Friday to push its market cap past $3.5 trillion. Nvidia wasnt far behind, trading up 1.3% on Friday with a market cap of $3.47 trillion, while Apple (NASDAQ:AAPL) also breached the $3 trillion mark with a 1% gain to reach $3.02 trillion. Microsofts stock has outpaced the broader Nasdaq (IND), rising 11% year-to-date compared to the indexs modest sub-1% gain. The software giant has been powered by robust growth in its cloud unit, Azure, where revenue jumped 28% year-over-year in Q3 FY25, and by its deepening partnership with OpenAI, which has driven strong demand for AI-powered services. Bernstein Societe Generale Group raised its price target on Microsoft to $540 from $520, citing significant upside potential as Azure continues to scale and AI integration expands across enterprise offerings. Bernstein analysts retained their Outperform rating, noting that Microsofts diversified revenue streamsfrom Office 365 subscriptions to LinkedIn and gamingprovide a hedge against macro uncertainties. Nvidias gains have been fueled by surging demand for its H100 and H200 GPUs, which dominate the AI data-center market, helping it close the gap with Microsoft. Apples performance, meanwhile, reflects resilient iPhone sales and growing services revenue, which has climbed 17% year-over-year to $21 billion in Q2 FY25. Why It Matters: Microsofts $3.5 trillion valuation underscores the escalating AI and cloud war between the tech titans, where gains in enterprise adoption and AI partnerships can translate directly into market-cap milestones. The battle for supremacy now hinges on execution in generative AI, data-center infrastructure and enterprise software integrations. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
1 Stock Down 34% This Year to Buy and Hold
Investors are withdrawing their money from stocks like Viking Therapeutics due to the current uncertainty. However, the biotech has a duo of mid-stage candidates that look incredibly promising. Though it carries above-average risk, Viking has significant upside potential. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues. The latter is true, at least to some extent, but Viking Therapeutics' thesis has not changed significantly this year. The drugmaker remains attractive compared to most of its similarly sized peers. Here is why. Viking Therapeutics is a clinical-stage biotech. That means the company has no product on the market, generates no revenue, and is consistently unprofitable. Investors aren't too keen on buying shares of companies that fit this profile when broader equities are experiencing significant volatility due to potential macroeconomic issues. In fairness, that makes sense. Clinical-stage biotechs carry above-average risk. Their products may never see the light of day outside the clinic, and even when they do, many do not generate substantial revenue. However, Viking Therapeutics is a bit different. The company is developing medicines across several areas with high unmet needs. First, there is the drugmaker's work in the weight management space. The anti-obesity drug market has experienced significant growth in recent years. Yet, analysts continue to predict that the best is yet to come. Viking Therapeutics' leading candidate in this area, VK2735, is a dual GLP-1/GIP agonist. The only approved medicine of this kind on the market is Eli Lilly's Zepbound, an undisputed leader. Being in the same class as Zepbound doesn't guarantee VK2735's success, but it's still worth pointing out that a similar mechanism of action that led to Zepbound's breakthrough and efficacy could also prove successful for Viking Therapeutics' crown jewel. And more importantly, the investigational medicine has produced better results than almost any other mid-stage candidate in weight management, outside of those being developed by Eli Lilly and Novo Nordisk. That's impressive for a mid-cap biotech, considering significantly larger drugmakers with far more resources are trying to dominate this market. Viking Therapeutics' other mid-stage program, VK2809, performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease with obesity as one of the main risk factors and whose prevalence is on the rise. However, the U.S. Food and Drug Administration approved just the first MASH medicine last year, although that will likely change soon. The point, though, is that VK2809 could join a relatively young market in a few years and generate massive sales down the road. These two candidates set Viking Therapeutics apart from other clinical-stage biotech companies. It's also worth noting that Viking Therapeutics recently signed a multiyear manufacturing agreement with privately held CordenPharma for VK2735. Per the terms of the deal, CordenPharma will manufacture more than a billion oral formulations of the medicine annually, as well as over 100 million autoinjectors and another 100 million syringes per year. Viking Therapeutics will make payments to CordenPharma, totaling $150 million through 2028. This deal highlights that Viking Therapeutics is already planning some post-commercial activity for its leading candidate. That's a great sign for investors. Viking Therapeutics is developing other candidates, including another weight management product that is still in preclinical studies. Following a similar blueprint, this product is a dual agonist that mimics the action of not just one but two gut hormones: amylin, which helps regulate blood sugar, and calcitonin, which regulates calcium levels. There is slow progress on that front, but Viking Therapeutics' commitment to innovation is impressive for such a small biotech. Now, Viking Therapeutics' most advanced programs could fail in phase 3 studies. If that happens, especially with VK2735, the stock price is likely to plummet. That's a significant risk to consider. That's why the stock is probably not suitable for risk-averse investors. However, those who are comfortable with volatility should strongly consider initiating a small position in the stock. If the business goes under, which isn't that rare for smaller biotech companies, your losses will be relatively small so long as the company makes a tiny portion of your overall portfolio. But there is significant upside potential that those who invest in Viking Therapeutics today could enjoy over the long run. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Stock Down 34% This Year to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
